Przybylska M, Bryszewska M, Nowicka U, Szosland K, Kedziora J, Epand R M
Department of Medical Biophysics, University of Lodz, Poland.
Clin Biochem. 1995 Dec;28(6):593-7. doi: 10.1016/0009-9120(95)00042-7.
Plasma and erythrocyte membrane cholesterol sulphate (CS) were measured in patients suffering from diabetes and Down's syndrome.
The procedure for separation and determination of CS comprised HPTLC (high-performance thin-layer chromatography) and densitometry.
The mean plasma and RBC membranes CS concentrations (+/- SD) of the control group (n = 16) was 188 +/- 47 micrograms/dL and 343 +/- 57 micrograms/10(12) RBC, respectively. In 15 patients with diabetes and 12 Down's syndrome patients substantially higher CS levels were found (diabetes: plasma-348 +/- 60 micrograms/dL; RBC membranes-646 +/- 113 micrograms/10(12) RBC; Down's syndrome: plasma-245 +/- 54 micrograms/dL; RBC membranes 427 +/- 74 micrograms/10(12) RBC). Analysis of variance and multiple comparison (Newman-Keuls test) show statistically significant differences between all samples both for erythrocytes, F(2.41) = 52.24, p < 0.05, and plasma, F(2.41) = 34.92, p < 0.05.
It is postulated that differences in CS levels may contribute to changes of erythrocyte properties in these pathological states.
对糖尿病患者和唐氏综合征患者的血浆及红细胞膜胆固醇硫酸酯（CS）进行检测。
CS的分离与测定方法包括高效薄层色谱法（HPTLC）和光密度测定法。
对照组（n = 16）的血浆和红细胞膜CS平均浓度（±标准差）分别为188 ± 47微克/分升和343 ± 57微克/10¹²个红细胞。在15例糖尿病患者和12例唐氏综合征患者中发现CS水平显著更高（糖尿病：血浆-348 ± 60微克/分升；红细胞膜-646 ± 113微克/10¹²个红细胞；唐氏综合征：血浆-245 ± 54微克/分升；红细胞膜427 ± 74微克/10¹²个红细胞）。方差分析和多重比较（纽曼-考尔斯检验）显示，所有样本的红细胞F(2,41) = 52.24，p < 0.05，血浆F(2,41) = 34.92，p < 0.05，均存在统计学显著差异。
据推测，CS水平的差异可能导致这些病理状态下红细胞特性的改变。
